Bone Cancer: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 6, 2013, Pages 688-723

  Sybil Biermann, J ^a   Adkins, Douglas R ^b   Agulnik, Mark ^c   Benjamin, Robert S ^d   Brigman, Brian ^e   Butrynski, James E ^f   Cheong, David ^g   Chow, Warren ^h   Curry, William T ⁱ   Frassica, Deborah A ^j   Frassica, Frank J ^j   Hande, Kenneth R ^k   Hornicek, Francis J ⁱ   Jones, Robin L ^l   Mayerson, Joel ^m   McGarry, Sean V ⁿ   McGrath, Brian ^o   Morris, Carol D ^p   O'donnell, Richard J ^q   Lor Randall, R ^r   Santana, Victor M ^s   Satcher, Robert L ^d   Siegel, Herrick J ^t   Von Mehren, Margaret ^u   Bergman, Mary Anne ^u   Sundar, Hema ^u   more..

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e DUKE CANCER INSTITUTE   (United States)

^f Dana Farber Brigham and Women's Cancer Center   (Australia)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h City of Hope Comprehensive Cancer Center   (Australia)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k VANDERBILT INGRAM CANCER CENTER   (United States)

^l USA   (Australia)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^o ROSWELL PARK CANCER INSTITUTE   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q UCSF Helen Diller Family Comprehensive Cancer Center   (Australia)

^r UNIVERSITY OF UTAH   (United States)

^s University of Tennessee   (Australia)

^t UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^u Chase Cancer Center   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; METHOTREXATE; PEGINTERFERON; RAPAMYCIN; SORAFENIB; SUNITINIB; TOPOTECAN;

ARTICLE; BONE BIOPSY; BONE CANCER; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHORDOMA; DRUG MEGADOSE; GIANT CELL TUMOR; HUMAN; NONHUMAN; OSTEOSARCOMA; PRACTICE GUIDELINE; SYSTEMIC THERAPY; BONE NEOPLASMS;

BONE NEOPLASMS; HUMANS; NEOPLASM STAGING;

EID: 84879368179     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0088     Document Type: Article

References (234)

1. Unni KK. Dahlin's Bone Tumors: General Aspects and Data on 11, 087 Cases. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1996.
2. Chow W, Haglund K, Randall RL. Bone sarcomas. In: Haller DG, Wagman LD, Camphausen C, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach Medical, Surgical, & Radiation Oncology. 14th ed. Norwalk, CT: UBM Medica LLC; 2011.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
4. Fletcher D, Unni K, Mertens F. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002.
5. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12:1-11. (Pubitemid 32125896)
6. Walcott BP, Nahed BV, Mohyeldin A, et al. Chordoma: current concepts, management, and future directions. Lancet Oncol 2012;13:e69-76.
7. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000;18:204-213. (Pubitemid 30036354)
8. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294-299. (Pubitemid 24236016)
9. Denny CT. Gene rearrangements in Ewing's sarcoma. Cancer Invest 1996;14:83-88. (Pubitemid 26076811)
10. Burchill SA. Molecular abnormalities in Ewing's sarcoma. Expert Rev Anticancer Ther 2008;8:1675-1687.
11. Calvert GT, Randall RL, Jones KB, et al. At-risk populations for osteosarcoma: the syndromes and beyond. Sarcoma 2012;2012:152382.
12. Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma 2012;2012:627254.
13. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238. (Pubitemid 120031831)
14. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994;12:925-930. (Pubitemid 24145318)
15. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 2012;118:1387-1396.
16. Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res 2009;152:15-32.
17. MacCarthy A, Bayne AM, Draper GJ, et al. Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004. Br J Ophthalmol 2009;93:1159-1162.
18. Kalra S, Grimer RJ, Spooner D, et al. Radiation-induced sarcomas of bone: factors that affect outcome. J Bone Joint Surg Br 2007;89:808-813. (Pubitemid 47180203)
19. Mavrogenis AF, Pala E, Guerra G, Ruggieri P. Post-radiation sarcomas. Clinical outcome of 52 Patients. J Surg Oncol 2012;105:570-576.
20. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006;11:503-519. (Pubitemid 43788277)
21. Subbiah V, Anderson P, Lazar AJ, et al. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 2009;10:126-140.
22. Federman N, Bernthal N, Eilber FC, Tap WD. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 2009;10:82-93.
23. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114.
24. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21:2011-2018. (Pubitemid 46606391)
25. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980:106-120. (Pubitemid 11217753)
26. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931. (Pubitemid 46655598)
27. Rougraff BT, Kneisl JS, Simon MA. Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am 1993;75:1276-1281. (Pubitemid 23331225)
28. Heck RK, Peabody TD, Simon MA. Staging of primary malignancies of bone. CA Cancer J Clin 2006;56:366-375. (Pubitemid 44903910)
29. Kumar J, Seith A, Kumar A, et al. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: comparison with skeletal scintigraphy and FDG PET/CT. Pediatr Radiol 2008;38:953-962.
30. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-236. (Pubitemid 32578088)
31. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369-373. (Pubitemid 44297249)
32. Volker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007;25:5435-5441. (Pubitemid 350232220)
33. Hawkins DS, Rajendran JG, Conrad EU, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]- fluorodeoxy-D-glucose positron emission tomography. Cancer 2002;94:3277-3284. (Pubitemid 34670512)
34. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828-8834. (Pubitemid 46211529)
35. Hawkins DS, Conrad EU 3rd, Butrynski JE, et al. [F-18]- fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 2009;115:3519-3525.
36. Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012;30:914-920.
37. Mammar H, Kerrou K, Nataf V, et al. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting. Int J Radiat Oncol Biol Phys 2012;84:681-687.
38. Liu PT, Valadez SD, Chivers FS, et al. Anatomically based guidelines for core needle biopsy of bone tumors: implications for limb-sparing surgery. Radiographics 2007;27:189-205; discussion 206.
39. Huang AJ, Kattapuram SV. Musculoskeletal neoplasms: biopsy and intervention. Radiol Clin North Am 2011;49:1287-1305.
40. Ashford RU, McCarthy SW, Scolyer RA, et al. Surgical biopsy with intra-operative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas. J Bone Joint Surg Br 2006;88:1207-1211.
41. Skrzynski MC, Biermann JS, Montag A, Simon MA. Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. J Bone Joint Surg Am 1996;78:644-649. (Pubitemid 26154249)
42. Welker JA, Henshaw RM, Jelinek J, et al. The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer 2000;89:2677-2686.
43. Mitsuyoshi G, Naito N, Kawai A, et al. Accurate diagnosis of musculoskeletal lesions by core needle biopsy. J Surg Oncol 2006;94:21-27. (Pubitemid 43967718)
44. Adams SC, Potter BK, Pitcher DJ, Temple HT. Office-based core needle biopsy of bone and soft tissue malignancies: an accurate alternative to open biopsy with infrequent complications. Clin Orthop Relat Res 2010;468:2774-2780.
45. Gogna A, Peh WC, Munk PL. Image-guided musculoskeletal biopsy. Radiol Clin North Am 2008;46:455-473, v.
46. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996;78:656-663.
47. Davies NM, Livesley PJ, Cannon SR. Recurrence of an osteosarcoma in a needle biopsy track. J Bone Joint Surg Br 1993;75:977-978. (Pubitemid 23337248)
48. Saghieh S, Masrouha KZ, Musallam KM, et al. The risk of local recurrence along the core-needle biopsy tract in patients with bone sarcomas. Iowa Orthop J 2010;30:80-83.
49. Yang YJ, Damron TA. Comparison of needle core biopsy and fine-needle aspiration for diagnostic accuracy in musculoskeletal lesions. Arch Pathol Lab Med 2004;128:759-764. (Pubitemid 38856885)
50. Chugh R, Tawbi H, Lucas DR, et al. Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007;12:1344-1350. (Pubitemid 350232608)
51. Yamaguchi T, Suzuki S, Ishiiwa H, Ueda Y. Intraosseous benign notochordal cell tumours: overlooked precursors of classic chordomas? Histopathology 2004;44:597-602. (Pubitemid 38845106)
52. Deshpande V, Nielsen GP, Rosenthal DI, Rosenberg AE. Intraosseous benign notochord cell tumors (BNCT): further evidence supporting a relationship to chordoma. Am J Surg Pathol 2007;31:1573-1577. (Pubitemid 47482472)
53. Yamaguchi T, Iwata J, Sugihara S, et al. Distinguishing benign notochordal cell tumors from vertebral chordoma. Skeletal Radiol 2008;37:291-299.
54. Nishiguchi T, Mochizuki K, Ohsawa M, et al. Differentiating benign notochordal cell tumors from chordomas: radiographic features on MRI, CT, and tomography. AJR Am J Roentgenol 2011;196:644-650.
55. Meyers SP, Hirsch WL Jr, Curtin HD, et al. Chordomas of the skull base: MR features. AJNR Am J Neuroradiol 1992;13:1627- 1636.
56. Weber AL, Liebsch NJ, Sanchez R, Sweriduk ST Jr. Chordomas of the skull base. Radiologic and clinical evaluation. Neuroimaging Clin N Am 1994;4:515-527. (Pubitemid 24283748)
57. Rosenthal DI, Scott JA, Mankin HJ, et al. Sacrococcygeal chordoma: magnetic resonance imaging and computed tomography. AJR Am J Roentgenol 1985;145:143-147. (Pubitemid 15022886)
58. Plathow C, Weber MA, Debus J, Kauczor HU. [Imaging of sacral chordoma: comparison between MRI and CT]. Radiologe 2005;45:63-68. (Pubitemid 40175004)
59. Sung MS, Lee GK, Kang HS, et al. Sacrococcygeal chordoma: MR imaging in 30 patients. Skeletal Radiol 2005;34:87-94. (Pubitemid 40174013)
60. Meyer JE, Lepke RA, Lindfors KK, et al. Chordomas: their CT appearance in the cervical, thoracic and lumbar spine. Radiology 1984;153:693-696. (Pubitemid 15186421)
61. Ducou le Pointe H, Brugieres P, Chevalier X, et al. Imaging of chordomas of the mobile spine. J Neuroradiol 1991;18:267-276.
62. Ferraresi V, Nuzzo C, Zoccali C, et al. Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer 2010;10:22.
63. Jawad MU, Scully SP. Surgery significantly improves survival in patients with chordoma. Spine (Phila Pa 1976) 2010;35:117-123.
64. Fuchs B, Dickey ID, Yaszemski MJ, et al. Operative management of sacral chordoma. J Bone Joint Surg Am 2005;87:2211-2216. (Pubitemid 41407545)
65. Ruggieri P, Angelini A, Ussia G, et al. Surgical margins and local control in resection of sacral chordomas. Clin Orthop Relat Res 2010;468:2939-2947.
66. Stacchiotti S, Casali PG, Lo Vullo S, et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 2010;17:211-219.
67. Forsyth PA, Cascino TL, Shaw EG, et al. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993;78:741-747. (Pubitemid 23121915)
68. Tzortzidis F, Elahi F, Wright D, et al. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 2006;59:230-237.
69. Sen C, Triana AI, Berglind N, et al. Clival chordomas: clinical management, results, and complications in 71 patients. J Neurosurg 2010;113:1059-1071.
70. Wu Z, Zhang J, Zhang L, et al. Prognostic factors for long-term outcome of patients with surgical resection of skull base chordomas-106 cases review in one institution. Neurosurg Rev 2010;33:451-456.
71. Di Maio S, Temkin N, Ramanathan D, Sekhar LN. Current comprehensive management of cranial base chordomas: 10-year meta-analysis of observational studies. J Neurosurg 2011;115:1094-1105.
72. Boriani S, Bandiera S, Biagini R, et al. Chordoma of the mobile spine: fifty years of experience. Spine (Phila Pa 1976) 2006;31:493-503. (Pubitemid 43361752)
73. Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996;41:67-72.
74. Foweraker KL, Burton KE, Maynard SE, et al. High-dose radiotherapy in the management of chordoma and chondrosarcoma of the skull base and cervical spine: Part 1-clinical outcomes. Clin Oncol (R Coll Radiol) 2007;19:509-516. (Pubitemid 47181180)
75. Wagner TD, Kobayashi W, Dean S, et al. Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone. Int J Radiat Oncol Biol Phys 2009;73:259-266.
76. Jian BJ, Bloch OG, Yang I, et al. Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol 2010;98:101- 108.
77. Moojen WA, Vleggeert-Lankamp CL, Krol AD, Dijkstra SP. Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable. Spine (Phila Pa 1976) 2011;36:E656-E661.
78. Potluri S, Jefferies SJ, Jena R, et al. Residual postoperative tumour volume predicts outcome after high-dose radiotherapy for chordoma and chondrosarcoma of the skull base and spine. Clin Oncol (R Coll Radiol) 2011;23:199-208.
79. Fagundes MA, Hug EB, Liebsch NJ, et al. Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys 1995;33:579-584.
80. Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999;91:432-439. (Pubitemid 29404435)
81. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999;175(Suppl 2):57-63. (Pubitemid 29533454)
82. Noel G, Habrand JL, Mammar H, et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protontherapie D'Orsay experience. Int J Radiat Oncol Biol Phys 2001;51:392-398. (Pubitemid 32884285)
83. Noel G, Feuvret L, Ferrand R, et al. Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas. Neurosurgery 2004;55:1252-1260. (Pubitemid 39612863)
84. Noel G, Feuvret L, Calugaru V, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 2005;44:700-708. (Pubitemid 41547070)
85. Park L, Delaney TF, Liebsch NJ, et al. Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006;65:1514-1521. (Pubitemid 44425209)
86. Staab A, Rutz HP, Ares C, et al. Spot-scanning-based proton therapy for extracranial chordoma. Int J Radiat Oncol Biol Phys 2011;81:489-496.
87. Yasuda M, Bresson D, Chibbaro S, et al. Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients. Neurosurg Rev 2012;35:171-182.
88. Schulz-Ertner D, Nikoghosyan A, Thilmann C, et al. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys 2004;58:631-640. (Pubitemid 38142491)
89. Schulz-Ertner D, Karger CP, Feuerhake A, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007;68:449-457. (Pubitemid 46694169)
90. Takahashi S, Kawase T, Yoshida K, et al. Skull base chordomas: efficacy of surgery followed by carbon ion radiotherapy. Acta Neurochir (Wien) 2009;151:759-769.
91. Imai R, Kamada T, Sugahara S, et al. Carbon ion radiotherapy for sacral chordoma. Br J Radiol 2011;84 Spec No 1:48-54.
92. Nishida Y, Kamada T, Imai R, et al. Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery. Int J Radiat Oncol Biol Phys 2011;79:110-116.
93. Gabriele P, Macias V, Stasi M, et al. Feasibility of intensity-modulated radiation therapy in the treatment of advanced cervical chordoma. Tumori 2003;89:298-304. (Pubitemid 37014123)
94. Yoneoka Y, Tsumanuma I, Fukuda M, et al. Cranial base chordoma-long term outcome and review of the literature. Acta Neurochir (Wien) 2008;150:773-778.
95. Zabel-du Bois A, Nikoghosyan A, Schwahofer A, et al. Intensity modulated radiotherapy in the management of sacral chordoma in primary versus recurrent disease. Radiother Oncol 2010;97:408- 412.
96. Kano H, Iqbal FO, Sheehan J, et al. Stereotactic radiosurgery for chordoma: a report from the North American Gamma Knife Consortium. Neurosurgery 2011;68:379-389.
97. Bugoci DM, Girvigian MR, Chen JCT, et al. Photon-based Fractionated Stereotactic Radiotherapy for Postoperative Treatment of Skull Base Chordomas. Am J Clin Oncol 2012.
98. Fleming GF, Heimann PS, Stephens JK, et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993;72:714-718. (Pubitemid 23215255)
99. Tamborini E, Miselli F, Negri T, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006;12:6920-6928. (Pubitemid 44974484)
100. Tamborini E, Virdis E, Negri T, et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol 2010;12:776-789.
101. Casali PG, Stacchiotti S, Grosso F, et al. Adding cisplatin (CDDP) to imatinib (IM) re-establishes tumor response following secondary resistance to IM in advanced chordoma [abstract]. J Clin Oncol 2007;25:Abstract 10038.
102. Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009;20:1886- 1894.
103. Singhal N, Kotasek D, Parnis FX. Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 2009;20:953-955.
104. Launay SG, Chetaille B, Medina F, et al. Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review. BMC Cancer 2011;11:423.
105. Linden O, Ehinger M, Kinhult S, et al. Cetuximab and EGFR inhibitors in patients with neurological symptoms due to chordoma (abstract). J Clin Oncol 2012;30(Suppl):Abstract 10024.
106. Thieblemont C, Biron P, Rocher F, et al. Prognostic factors in chordoma: role of postoperative radiotherapy. Eur J Cancer 1995;31A:2255-2259. (Pubitemid 26050568)
107. Boriani S, Saravanja D, Yamada Y, et al. Challenges of local recurrence and cure in low grade malignant tumors of the spine. Spine (Phila Pa 1976) 2009;34:S48-S57.
108. Chambers PW, Schwinn CP. Chordoma. A clinicopathologic study of metastasis. Am J Clin Pathol 1979;72:765-776. (Pubitemid 10158892)
109. McPherson CM, Suki D, McCutcheon IE, et al. Metastatic disease from spinal chordoma: a 10-year experience. J Neurosurg Spine 2006;5:277-280. (Pubitemid 47325364)
110. Dominkus M, Ruggieri P, Bertoni F, et al. Histologically verified lung metastases in benign giant cell tumours-14 cases from a single institution. Int Orthop 2006;30:499-504. (Pubitemid 44900558)
111. Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res 2010;468:827-833.
112. Anract P, De Pinieux G, Cottias P, et al. Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop 1998;22:19-26. (Pubitemid 28132804)
113. Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer 2003;97:2520-2529. (Pubitemid 36542492)
114. Purohit S, Pardiwala DN. Imaging of giant cell tumor of bone. Indian J Orthop 2007;41:91-96.
115. Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol 2009;21:338-344.
116. Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 2006;30:484-489. (Pubitemid 44900556)
117. McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am 1986;68:235-242. (Pubitemid 16108701)
118. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987;69:106-114. (Pubitemid 17030377)
119. Saiz P, Virkus W, Piasecki P, et al. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res 2004:221-226. (Pubitemid 38890882)
120. Malek F, Krueger P, Hatmi ZN, et al. Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop 2006;30:495-498. (Pubitemid 44913852)
121. Kivioja AH, Blomqvist C, Hietaniemi K, et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008;79:86-93. (Pubitemid 351271888)
122. Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 2010;36:1-7.
123. Klenke FM, Wenger DE, Inwards CY, et al. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011;469:591-599.
124. O'Donnell RJ, Springfield DS, Motwani HK, et al. Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994;76:1827-1833.
125. Blackley HR, Wunder JS, Davis AM, et al. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999;81:811-820. (Pubitemid 29297559)
126. Prosser GH, Baloch KG, Tillman RM, et al. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res 2005:211-218. (Pubitemid 40798665)
127. Becker WT, Dohle J, Bernd L, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008;90:1060-1067. (Pubitemid 351632651)
128. Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008;134:969-978.
129. Pietschmann MF, Dietz RA, Utzschneider S, et al. The influence of adjuvants on local recurrence rate in giant cell tumour of the bone. Acta Chir Belg 2010;110:584-589.
130. Trieb K, Bitzan P, Lang S, et al. Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001;27:200-202. (Pubitemid 32621735)
131. Turcotte RE, Wunder JS, Isler MH, et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002:248-258. (Pubitemid 34442036)
132. Ruggieri P, Mavrogenis AF, Ussia G, et al. Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor. Clin Orthop Relat Res 2010;468:2954-2961.
133. Oda Y, Miura H, Tsuneyoshi M, Iwamoto Y. Giant cell tumor of bone: oncological and functional results of long-term follow-up. Jpn J Clin Oncol 1998;28:323-328. (Pubitemid 128522957)
134. Boons HW, Keijser LC, Schreuder HW, et al. Oncologic and functional results after treatment of giant cell tumors of bone. Arch Orthop Trauma Surg 2002;122:17-23. (Pubitemid 36067904)
135. Su YP, Chen WM, Chen TH. Giant-cell tumors of bone: an analysis of 87 cases. Int Orthop 2004;28:239-243.
136. Rastogi S, Prashanth I, Khan SA, et al. Giant cell tumor of bone: is curettage the answer? Indian J Orthop 2007;41:109-114.
137. Guo W, Sun X, Zang J, Qu H. Intralesional excision versus wide resection for giant cell tumor involving the acetabulum: which is better? Clin Orthop Relat Res 2012;470:1213-1220.
138. Labs K, Perka C, Schmidt RG. Treatment of stages 2 and 3 giant-cell tumor. Arch Orthop Trauma Surg 2001;121:83-86. (Pubitemid 32124004)
139. Mankin HJ, Hornicek FJ. Treatment of giant cell tumors with allograft transplants: a 30-year study. Clin Orthop Relat Res 2005;439:144-150. (Pubitemid 41416364)
140. Mendenhall WM, Zlotecki RA, Scarborough MT, et al. Giant cell tumor of bone. Am J Clin Oncol 2006;29:96-99. (Pubitemid 44356723)
141. Saini R, Bali K, Bachhal V, et al. En bloc excision and autogenous fibular reconstruction for aggressive giant cell tumor of distal radius: a report of 12 cases and review of literature. J Orthop Surg Res 2011;6:14.
142. Dahlin DC. Caldwell Lecture. Giant cell tumor of bone: highlights of 407 cases. AJR Am J Roentgenol 1985;144:955-960. (Pubitemid 15032464)
143. Schwartz LH, Okunieff PG, Rosenberg A, Suit HD. Radiation therapy in the treatment of difficult giant cell tumors. Int J Radiat Oncol Biol Phys 1989;17:1085-1088. (Pubitemid 19279516)
144. Bennett CJ, Marcus RB, Million RR, Enneking WF. Radiation therapy for giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1993;26:299-304. (Pubitemid 23156977)
145. Chakravarti A, Spiro IJ, Hug EB, et al. Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg Am 1999;81:1566-1573.
146. Nair MK, Jyothirmayi R. Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1999;43:1065-1069. (Pubitemid 29144796)
147. Miszczyk L, Wydmanski J, Spindel J. Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys 2001;49:1239-1242. (Pubitemid 32294303)
148. Caudell JJ, Ballo MT, Zagars GK, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 2003;57:158-165. (Pubitemid 36959751)
149. Feigenberg SJ, Marcus RB Jr, Zlotecki RA, et al. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res 2003:207- 216. (Pubitemid 36667279)
150. Ruka W, Rutkowski P, Morysinski T, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys 2010;78:494-498.
151. Bhatia S, Miszczyk L, Roelandts M, et al. Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study. Rare Tumors 2011;3.
152. Kriz J, Eich HT, Mucke R, et al. Radiotherapy for giant cell tumors of the bone: a safe and effective treatment modality. Anticancer Res 2012;32:2069-2073.
153. Hug EB, Muenter MW, Adams JA, et al. 3-D-conformal radiation therapy for pediatric giant cell tumors of the skull base. Strahlenther Onkol 2002;178:239-244. (Pubitemid 34534805)
154. Roeder F, Timke C, Zwicker F, et al. Intensity modulated radiotherapy (IMRT) in benign giant cell tumors-a single institution case series and a short review of the literature. Radiat Oncol 2010;5:18.
155. Lin PP, Guzel VB, Moura MF, et al. Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer 2002;95:1317-1325. (Pubitemid 35013068)
156. Hosalkar HS, Jones KJ, King JJ, Lackman RD. Serial arterial embolization for large sacral giant-cell tumors: mid- to long-term results. Spine (Phila Pa 1976) 2007;32:1107-1115. (Pubitemid 46685990)
157. Onishi H, Kaya M, Wada T, et al. Giant cell tumor of the sacrum treated with selective arterial embolization. Int J Clin Oncol 2010;15:416-419.
158. Emori M, Kaya M, Sasaki M, et al. Pre-operative selective arterial embolization as a neoadjuvant therapy for proximal humerus giant cell tumor of bone: radiological and histological evaluation. Jpn J Clin Oncol 2012;42:851-855.
159. Kaiser U, Neumann K, Havemann K. Generalised giant-cell tumour of bone: successful treatment of pulmonary metastases with interferon alpha, a case report. J Cancer Res Clin Oncol 1993;119:301-303. (Pubitemid 23055433)
160. Kaban LB, Troulis MJ, Ebb D, et al. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 2002;60:1103-1111.
161. Yasko AW. Interferon therapy for giant cell tumor of bone. Current Opinion in Orthopaedics 2006;17:568-572. (Pubitemid 44673423)
162. Wei F, Liu X, Liu Z, et al. Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases. Spine (Phila Pa 1976) 2010;35:E1418-1422.
163. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-280.
164. Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18:4415-4424.
165. Cheng JC, Johnston JO. Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. Clin Orthop Relat Res 1997:205-214. (Pubitemid 27203465)
166. Siebenrock KA, Unni KK, Rock MG. Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br 1998;80:43-47.
167. Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 2006;125:555-581.
168. Antonescu CR, Huvos AG. Low-grade osteogenic sarcoma arising in medullary and surface osseous locations. Am J Clin Pathol 2000;114 Suppl:S90-103.
169. Sheth DS, Yasko AW, Raymond AK, et al. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer 1996;78:2136-2145. (Pubitemid 26367606)
170. Bertoni F, Bacchini P, Staals EL, Davidovitz P. Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer 2005;103:2373-2382. (Pubitemid 40686584)
171. Okada K, Unni KK, Swee RG, Sim FH. High grade surface osteosarcoma: a clinicopathologic study of 46 cases. Cancer 1999;85:1044-1054. (Pubitemid 29115582)
172. Staals EL, Bacchini P, Bertoni F. High-grade surface osteosarcoma: a review of 25 cases from the Rizzoli Institute. Cancer 2008;112:1592-1599. (Pubitemid 351441173)
173. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-431. (Pubitemid 24056419)
174. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001;12:1145-1150. (Pubitemid 32834497)
175. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2002;20:776- 790. (Pubitemid 34111386)
176. Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori 2004;90:478-484. (Pubitemid 39556797)
177. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-1161.
178. Whelan JS, Jinks RC, McTiernan A, et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol 2012;23:1607-1616.
179. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000;7:339-346.
180. Daw NC, Billups CA, Rodriguez-Galindo C, et al. Metastatic osteosarcoma. Cancer 2006;106:403-412.
181. Marulanda GA, Henderson ER, Johnson DA, et al. Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control 2008;15:13-20. (Pubitemid 351481988)
182. Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br 2002;84:88-92.
183. Mavrogenis AF, Abati CN, Romagnoli C, Ruggieri P. Similar survival but better function for patients after limb salvage versus amputation for distal tibia osteosarcoma. Clin Orthop Relat Res 2012;470:1735-1748.
184. Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. 1986. J Bone Joint Surg Am 2005;87:2822. (Pubitemid 41747052)
185. Aksnes LH, Bauer HC, Jebsen NL, et al. Limb-sparing surgery preserves more function than amputation: a Scandinavian sarcoma group study of 118 patients. J Bone Joint Surg Br 2008;90:786-794. (Pubitemid 351859809)
186. Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol 2002;20:4493-4501. (Pubitemid 35334762)
187. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984;2:617-624. (Pubitemid 14025617)
188. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600- 1606. (Pubitemid 16118216)
189. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-26. (Pubitemid 17007852)
190. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991:8-14.
191. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
192. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003;21:1574- 1580. (Pubitemid 46594112)
193. Bramwell V, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992;10:1579-1591. (Pubitemid 23057988)
194. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-1161.
195. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893- 899. (Pubitemid 28440449)
196. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-4027. (Pubitemid 32038393)
197. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001;37:2030-2039. (Pubitemid 32938106)
198. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23:8845-8852. (Pubitemid 46211531)
199. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112-128.
200. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008;26:633-638. (Pubitemid 351264359)
201. Basaran M, Bavbek ES, Saglam S, et al. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology 2007;72:255-260. (Pubitemid 351161619)
202. Le Deley MC, Guinebretiere JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 2007;43:752- 761.
203. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84. (Pubitemid 27020560)
204. Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005;41:2079-2085. (Pubitemid 41337949)
205. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009;115:5339-5348.
206. Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. Cancer 2011;117:1731-1735.
207. Grimer RJ, Bielack S, Flege S, et al. Periosteal osteosarcoma-a European review of outcome. Eur J Cancer 2005;41:2806-2811. (Pubitemid 41713117)
208. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS- 82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988;6:329-337. (Pubitemid 18065939)
209. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39:488-494. (Pubitemid 36173693)
210. Smeland S, Bruland OS, Hjorth L, et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop 2011;82:211-216.
211. Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: An Italian Sarcoma Group trial ISG/OS-1. J Clin Oncol 2012;30:2112-2118.
212. Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011;117:4522-4530.
213. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11:449-453. (Pubitemid 23071040)
214. Bacci G, Briccoli A, Mercuri M, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998;10:69-76. (Pubitemid 28092412)
215. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003;14:1126-1134. (Pubitemid 36950179)
216. Winkler K, Torggler S, Beron G, et al. [Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative osteosarcoma studies COSS-80 and COSS-82]. Onkologie 1989;12:92-96. (Pubitemid 19139586)
217. Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 1997;79:245-254. (Pubitemid 27029888)
218. Tabone MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994;12:2614-2620. (Pubitemid 24379647)
219. Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995;75:1084-1093.
220. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003;21:710-715. (Pubitemid 46621907)
221. Buddingh EP, Anninga JK, Versteegh MI, et al. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer 2010;54:216-221.
222. Briccoli A, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985- 2005. Surg Oncol 2010;19:193-199.
223. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009;27:557-565.
224. Berger M, Grignani G, Ferrari S, et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 2009;115:2980-2987.
225. Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997;33:232- 237.
226. Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000;45:177-181. (Pubitemid 30090250)
227. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-425.
228. Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469. (Pubitemid 32730082)
229. Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005;44:338-347. (Pubitemid 40316026)
230. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:189-196. (Pubitemid 34032611)
231. Loeb DM, Garrett-Mayer E, Hobbs RF, et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer 2009;115:2514-2522.
232. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012;23:508-516.
233. Lashkari A, Chow WA, Valdes F, et al. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res 2009;29:3281-3288.
234. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian Sarcoma Group study. J Clin Oncol 2002;20:2150-2156. (Pubitemid 34408807)